| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Stratagene Holding Corporation |
| 11011 North Torrey Pines Road, La Jolla, CA 92037 * (858) 535-5400 |
| Business Description | The company develops and manufacturers biological products and instruments designed to improve the speed and accuracy of molecular biology and genomics research. |
|
Filing Information Not yet | |||
| To Trade As | STGN (NASNTL) | Industry | Pharmaceutical (SIC 2836) |
| Type of Stock Offered | Common Shares | Filing Date | 3/10/00 |
| Domestic Shares Filed | 0 | Filing Price | - - |
| Foreign Shares Filed | 0 | Offering Amount | $150,000,000 |
| Company Shares | 0 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Merrill Lynch & Co. | Lead Manager | (212) 449-4600 |
| Dain Rauscher Wessels | Co-manager | (612) 371-2818 |
| Prudential Vector Healthcare | Co-manager | (800) 546-1231 |
| Salomon Smith Barney | Co-manager | (212) 723-7300 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/95 | 12/31/96 | 12/31/97 | 12/31/98 | 12/31/99 | ||
| Revenues | 39.933 | 44.326 | 49.387 | 53.179 | 51.318 | - | - |
| Income from Oper. | 8.788 | 10.995 | 12.100 | 8.156 | -2.647 | - | - |
| Net Income | 3.132 | 5.788 | 4.679 | 2.725 | -2.475 | - | - |
| E.P.S | 0.100 | 0.190 | 0.150 | 0.090 | -0.080 | - | - |
| Revenue Growth (%) | 11.00 | 11.42 | 7.68 | -3.500 | - | ||
| Net Income Growth (%) | 84.80 | -19.16 | -41.76 | - | - | ||
| Oper. Profit Margin (%) | 22.01 | 24.80 | 24.50 | 15.34 | - | - | - |
| Net Profit Margin (%) | 7.84 | 13.06 | 9.47 | 5.12 | - | - | - |
| Cash Flow - Oper. | 1.35 | - | - | ||||
| Cash Flow - Inv. | -0.52 | - | - | ||||
| Cash Flow - Fin. | -6.24 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 36.48 | Current Assets | 20.49 | Current Ratio | 1.62 |
| Total Liab. | 43.58 | Current Liab. | 12.68 | Debt Ratio | 119.47% |
| Total Equity | -7.10 | Working Cap. | 7.81 | Debt to Equity Ratio | - |
| Cash | 3.10 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research and development; expansion of our sales and marketing organization; repayment of debt; payment in connection with the termination of phantom stock rights; the acquisition of BioCrest Holdings, LLC; and general corporate purposes and other corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Latham & Watkins |
| Bank's Law Firm | Debevoise & Plimpton |
| Registrar/Transfer Agent | ChaseMellon Shareholder Services, L.L.C. |
| Auditor | KPMG LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Joseph A. Sorge, M.D. | 75.50 | |
| TCW Special Credits Fund V -- The Principal Fund | 22.40 | |
| Note: represents ownership of 5% or more prior to the offering. | ||